FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-02-20

Price

$14.34

-0.07%

Score12.5Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 3

Volume0.7xvs 20d avg

Analysis

FOLD is currently trading as a low-volatility merger arbitrage play, tethered to the pending $14.50/share all-cash acquisition by BioMarin (expected close Q2 2026). The 'Alpha Male' and 'Steady Climb' signals are effectively false positives for directional upside; they are instead detecting the stock's decoupling from broader macro volatility (VIX 20.2) due to the deal peg. Recent full-year earnings (Feb 20) showed strong 17% revenue growth, which fundamentally de-risks the floor should the deal encounter unexpected antitrust friction, but upside is strictly capped at the deal price.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

**Arb Spread Opportunity:** Trading at $14.34 vs. $14.50 deal price offers a ~1.1% spread; tight credit spreads (0.79% OAS) suggest financing is secure.
**Fundamental Floor:** Strong Feb 20 earnings ($634M rev, +17% YoY) confirm the business quality, providing a safety net if the merger breaks.
**Signal Noise:** Technical signals are flagging 'Relative Strength' because FOLD is flat while the market chops; do not misinterpret this as a breakout setup beyond $14.50.

← Back to 2026-02-20 View Full FOLD History →Yahoo Finance &nearr;